Visit | Mean | SD | Change from screen (%) | p Value | |
Mean eosinophils per hpf (ECP+ cells) | |||||
Mepolizumab (n = 5) | Screening | 73.21 | 50.57 | ||
Week 4 | 33.83 | 22.82 | −54 | 0.030 | |
Week 13 | 32.72 | 28.32 | −55 | 0.011 | |
Placebo (n = 6) | Screening | 56.71 | 33.43 | ||
Week 4 | 53.99 | 24.51 | −5 | NS | |
Week 13 | 52.68 | 28.75 | −7 | NS | |
T cells per hpf (CD3+ cells) | |||||
Mepolizumab (n = 5) | Screening | 69.95 | 19.19 | ||
Week 4 | 67.86 | 11.30 | −3 | NS | |
Week 13 | 67.86 | 21.94 | −3 | NS | |
Placebo (n = 6) | Screening | 63.89 | 18.06 | ||
Week 4 | 66.99 | 17.28 | +5 | NS | |
Week 13 | 66.56 | 23.65 | +4 | NS | |
Mast cells per hpf (tryptase+ cells) | |||||
Mepolizumab (n = 5) | Screening | 25.41 | 15.18 | ||
Week 4 | 23.77 | 11.02 | −6 | NS | |
Week 13 | 20.57 | 10.62 | −19 | NS | |
Placebo (n = 6) | Screening | 23.02 | 13.19 | ||
Week 4 | 26.67 | 12.33 | +15 | NS | |
Week 13 | 22.59 | 13.18 | −2 | NS |
ECP, eosinophil cationic protein; hpf, high power field; NS, non-significant.